Nurix Therapeutics Inc NRIX

$15.48 -0.12 (-0.77%)

Valuation

Market cap
1,704,300,000
Revenue TTM
$83,980,000
Net income TTM
$-264,460,000
P/E (trailing)
7.07
P/E (forward)
14.31
Profit margin
-314.91%
Debt to equity
0.00

Trading

Volume
1,385,500
Avg volume
2,712,528
Day's range
$15.19 – $15.76
Shares out
109,250,000
Stochastic %K
6%
Beta
1.80
Analysts
Strong Buy
Price target
$33.50

Price

Company profile

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoi...

Show more

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, which is in Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. Nurix Therapeutics, Inc. has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Pfizer Inc. for co-development and co-commercialization of multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.

Industry
Biotechnology
Sector
Healthcare
Phone
415 660 5320
Website
https://www.nurixtx.com
Address
1600 Sierra Point Parkway, Brisbane, United States

Latest news

Stocktwits

MaxDanger Nov 12, 12:35 PM
$NRIX Between the cash and data released to date on their CLL degrader program, a market cap of 1.8 billion is too cheap. We have ash coming up in a couple weeks, any positive data could send this to the moon. This is too cheap here, I’m in at around $16 and think this should be a $30+ stock with where they sit with current programs, data released so far and cash position. Exciting times.
2 replies
Pika_Capital Nov 11, 6:07 PM
$NRIX those morons who sold me shares on that day are going to be regretting big time in few years
0 replies
Bli1 Nov 9, 4:35 PM
$NRIX long again.
0 replies
stjernerogvann Nov 9, 3:32 PM
$NRIX why did NRIX fall over the last month? I have an oncologist friend who recommended it at this same level and I saw it climb over a few months...but why has it fallen back?
1 replies
Rayvio_News_Filter Nov 9, 1:07 PM
$NRIX 🏥 Adneuris Therapeutics, Inc. submits a New Drug Application to the FDA for cebranopadol for moderate-to-severe acute pain, supported by positive Phase 3 ALLEVIATE-1 and ALLEVIATE-2 results. Curated for market relevance
0 replies
GTA_Terminal Nov 9, 8:01 AM
$NRIX Options Flow Leans to Puts: A Smart-Money Check on the Stock. $NRIX rose in the latest session, on heavier volume than usual. It's down about 43% from a week ago. Read the full article for the full details: https://globaltradersacademy.com/articles/nurix-nrix-options-flow-turns-bearish-a-smart-money-check-on-the-stock?utm_source=stocktwits&utm_medium=social
0 replies
oaksapollo Nov 5, 6:09 PM
$NRIX This deck is dated 10/27, still has STAT6 there. https://www.nurixtx.com/wp-content/uploads/2026/10/TPD-2026-HV-and-CLL-FINAL.pdf But most interesting is the data from the healthy subjects study. Safety looks extremely clean, and this is critical for bexo to move outside of the oncology space. No grade 3 AEs and across every single dose, no clear difference with placebo, with the exception of mild petechiae.
1 replies
LabPsycho Nov 5, 6:09 PM
$NRIX Exhibit A, below: Yesterday's rally appears to be the suspected sucker rally suggested below with market giving up most of the 3% gain from yesterday. I expect a cliff event for many biotech (and other) stocks by year end. Good luck.
0 replies